For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| General and administrative | 5,657 | |||
| Research and development (includes related party amounts of 0, 36, 0, and 58, respectively) | 1,328 | |||
| Total operating expenses | 6,985 | |||
| Loss from operations | -6,985 | |||
| Other income, net | 973 | |||
| Interest income | 746 | |||
| Interest expense | 0 | |||
| Total other income, net | 1,719 | |||
| Net loss | -5,266 | |||
| Unrealized gain (loss) on marketable securities | -158 | |||
| Total comprehensive loss | -5,424 | |||
| Basic EPS | -0.11 | |||
| Diluted EPS | -0.11 | |||
| Basic Average Shares | 50,114,308 | |||
| Diluted Average Shares | 50,114,308 | |||
HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX)